Patents matching “antibody”

US 11054423

Antibody-mediated neutralization of ebolaviruses

The Board of Regents of the University of Texas System · Granted Jul 6, 2021 · Expires Jul 1, 2041

US 11046755

Antibody based reagents that specifically recognize toxic oligomeric forms of tau

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 11040084

Stable antibody-drug conjugate, preparation method therefor, and use thereof

GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Jun 22, 2021 · Expires Jun 17, 2041

US 11033635

Antibody-STING agonist conjugates and their use in immunotherapy

The Board of Regents of the University of Texas System · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11021542

Humanized BCMA antibody and BCMA-CAR-T cells

Caribou Biosciences, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

US 11001641

Monoclonal antibody therapy for pancreas cancer

PRECISION BIOLOGICS, INC. · Granted May 11, 2021 · Expires May 6, 2041

US 10995150

Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

REGENERON PHARMACEUTICALS, INC. · Granted May 4, 2021 · Expires Apr 29, 2041

US 10982221

Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Apr 20, 2021 · Expires Apr 15, 2041

US 10966977

Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

TG Therapeutics, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

US 10946106

Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen

The Regents of the University of California · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10947317

NaPi2b-targeted antibody-drug conjugates and methods of use thereof

Mersana Therapeutics, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10947310

Fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. · Granted Mar 16, 2021 · Expires Mar 11, 2041

US 10934349

Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

US 10927182

Humanized BCMA antibody and BCMA-CAR-T cells

Caribou Biosciences, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

US 10899826

Pharmaceutical compositions for an anti-CGRP antagonist antibody

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 26, 2021 · Expires Jan 21, 2041

US 10899829

Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury

United States Government as represented by the Department of Veterans Affairs · Granted Jan 26, 2021 · Expires Jan 21, 2041

US 10875907

Filovirus antibody

The Government of the United States, as represented by the Secretary of the Army · Granted Dec 29, 2020 · Expires Dec 24, 2040

US 10849970

Antibody evolution immunogens

The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Dec 1, 2020 · Expires Nov 26, 2040

US 10844129

Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids

Inhibrx, Inc. · Granted Nov 24, 2020 · Expires Nov 19, 2040

US 10813952

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 27, 2020 · Expires Oct 22, 2040

US 10799596

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Oct 13, 2020 · Expires Oct 8, 2040

US 10792370

Antibody-drug conjugate

SHANGHAI MIRACOGEN INC. · Granted Oct 6, 2020 · Expires Oct 1, 2040

US 10786552

Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Nektar Therapeutics · Granted Sep 29, 2020 · Expires Sep 24, 2040

US 10780096

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA · Granted Sep 22, 2020 · Expires Sep 17, 2040